Erdafitinib Impurities refer to the unwanted or unintended substances that may be present in erdafitinib drug substance or drug product. These impurities can arise from various sources such as starting materials, synthetic process, degradation, or storage conditions. Identification, quantification, and control of these impurities are critical for ensuring the safety, efficacy, and quality of erdafitinib drug products. Regulatory agencies require manufacturers to conduct comprehensive impurity profiling and risk assessments to ensure compliance with the established
